Relieves bronchospasm. ANDA 76355, held by Nephron. Albuterol Sulfate.
As of Nov 16, 2026, ANDA 76355 (Albuterol Sulfate), held by Nephron, was first approved by FDA on Jun 28, 2004, with 4 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Albuterol inhalation solution is indicated for the relief of bronchospasm in patients 2 to 12 years of age with asthma (reversible obstructive airway disease).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 28, 2004 | Original application | Approved | None posted |
| Albuterol SulfateEQ 0.042% BASE · solution;inhalation | Albuterol Sulfate | Rx |
| Albuterol SulfateEQ 0.021% BASE · solution;inhalation | Albuterol Sulfate | Rx |
| Sep 13, 2011 | Supplement 12Labeling | Approved | None posted |
| Mar 31, 2010 | Supplement 7Labeling | Approved | None posted |
| Mar 29, 2007 | Supplement 4Labeling | Approved | None posted |
| Mar 22, 2005 | Supplement 1Labeling | Approved | None posted |
| Jun 28, 2004 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters